CAMBRIDGE, Mass.–(BUSINESS WIRE)–X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage
biopharmaceutical company focused on the development of novel
therapeutics for the treatment of rare diseases, announced today that it
has commenced an underwritten public offering of shares of its common
stock (or pre-funded warrants to purchase common stock in lieu thereof)
and Class A warrants to purchase its common stock. All of the securities
in the offering will be sold by X4. The offering is subject to market
and other conditions, and there can be no assurance as to whether or
when the offering may be completed or as to the actual size or terms of
the offering.
Cowen and Stifel are acting as joint book-running managers and
representatives of the underwriters for the offering. Canaccord Genuity
is acting as lead manager of the offering.
The offering will be made only by means of a written prospectus and
related prospectus supplement forming part of a shelf registration
statement on Form S-3 that was filed with the Securities and Exchange
Commission (SEC) on January 25, 2019 and declared effective by the SEC
on February 19, 2019. A preliminary prospectus supplement and
accompanying prospectus relating to and describing the terms of the
offering will be filed with the SEC and will be available at the SEC’s
website located at www.sec.gov,
copies of which may be obtained, when available, from Cowen and Company,
LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, Attn: Prospectus Department, or by telephone at
631-274-2806, and from Stifel, Nicolaus & Company, Incorporated,
Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco,
California 94104, or by telephone at 415-364-2720 or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
About X4 Pharmaceuticals
X4 Pharmaceuticals is developing novel therapeutics designed to improve
immune cell trafficking to treat rare diseases, including primary
immunodeficiencies and cancer. X4’s oral small molecule drug candidates
antagonize the CXCR4 pathway, which plays a central role in immune
surveillance. X4’s most advanced product candidate, mavorixafor
(X4P-001), will be commencing a global Phase 3 pivotal trial in patients
with WHIM syndrome, a rare genetic, primary immunodeficiency disease, in
the second quarter of 2019 and is currently also under investigation in
a Phase 2a clinical trial in clear cell renal cell carcinoma. X4 was
founded and is led by a team with extensive product development and
commercialization expertise, including several former members of the
Genzyme leadership team, and is located in Cambridge, Massachusetts.